Drug Approval | December 14, 2025
FDA completes inspection of SMS Pharma’s Vizag facility
The inspection concluded with one minor observation in Form 483
The inspection concluded with one minor observation in Form 483
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Subscribe To Our Newsletter & Stay Updated
